Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study

Hentrich, Marcus; Berger, Marcel; Wyen, Christoph; Siehl, Jan; Rockstroh, Jürgen K.; Müller, Markus; Fätkenheuer, Gerd; Seidel, Elisabeth; Nickelsen, Maike; Wolf, Timo; Rieke, A.; Schürmann, Dirk; Schmidmaier, Ralf; Planker, M.; Alt, Jürgen August; Mosthaf, Franz; Engert, Andreas; Arastéh, Keikawus; Hoffmann, Christian

doi:10.1200/jco.2012.41.8137

Cited by 112 publications

(78 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, current data from prospective and retrospective trials have shown promising results. In the prospective German multicenter study using a stage-adapted treatment approach, CR rates were 96% for early-stage favorable, 100% for early-stage unfavorable, and 86% for advanced-stage HL [54]. 2 comparative studies on ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) in HL showed that HIV infection did not adversely affect progression-free and event-free survival or OS [41,55].…”

Section: Hodgkin's Lymphomamentioning

confidence: 99%

“…Patients with early favorable disease should receive 2 cycles of ABVD with subsequent 20-Gy involved-field radiotherapy. 4 cycles of ABVD followed by 30-Gy involved-field radiotherapy is the treatment of choice for patients with early unfavorable disease, and patients with advanced stage should receive 6 cycles of BEA-COPP baseline (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisolone) or 6-8 cycles of ABVD [54].…”

Section: Hodgkin's Lymphomamentioning

confidence: 99%

See 1 more Smart Citation

HIV-Associated Malignant Lymphoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

Acquired immune deficiency syndrome (AIDS)-related lymphomas (ARL) still represent a relevant field of clinical research. For most histological subtypes of ARL, no optimal initial therapy has been clearly defined so far. Rituximab plus chemotherapy is feasible and effective and should be offered to all patients with CD20-positive ARL regardless of their CD4 cell count. Combination antiretroviral therapy (cART) should be given concomitantly with chemotherapy, bearing in mind potential drug-drug interactions. Appropriate treatment of ARL is determined by a number of factors such as lymphoma stage, performance status, comorbidities, histological subtype, and immunosuppression. Treatment should principally be the same as in human immunodeficiency virus (HIV)-negative lymphoma patients. In HIV-related Hodgkin's lymphoma, high cure rates have been achieved with stage-adapted treatment approaches, albeit with worse outcomes compared to immunocompetent patients.

show abstract

Section: Hodgkin's Lymphomamentioning

confidence: 99%

Section: Hodgkin's Lymphomamentioning

confidence: 99%

HIV-Associated Malignant Lymphoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several clinical trials (17)(18)(19)(20)(21) and observational studies (22)(23)(24) with HIV-infected lymphoma cases treated with HAART reported survival outcomes comparable to general patients with lymphoma. However, a few studies directly compared HIV-infected and HIV-uninfected patients with lymphoma and found inconsistent results.…”

Section: Introductionmentioning

confidence: 99%

HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy

Han

Jemal

Hulland

et al. 2017

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…The 2-year overall survival (OS) rate in the entire cohort was 90.7%. 62 However, BEACCOPP was toxic; dose reductions and delays were common, and treatment-related mortality was 7%. Our approach is to avoid BEACOPP in HIV-cHL, with the possible exception of responseadapted therapeutic escalation.…”

Section: Primary Chemotherapy For Hiv-chlmentioning

confidence: 99%

How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus

Uldrick

Little

2015

Blood

View full text Add to dashboard Cite

HIV-associated classical Hodgkin lymphoma (HIV-cHL) is an important complication of HIV disease in the era of effective combination antiretroviral therapy (cART). Generally, newly diagnosed HIV-cHL should be managed with curative intent. With modern HIV therapeutics, HIV-cHL treatment outcomes are largely comparable to those of the background population with cHL (non–HIV-cHL). To achieve these outcomes, particular attention must be given to managing HIV. This management includes understanding HIV as a comorbid condition with a spectrum of impact that is unique to each patient. Meticulous attention to drug-drug interactions is required to avoid toxicity and pharmacokinetic effects that can undermine cure. Relapsed and refractory HIV-cHL poses additional therapeutic challenges. The standard management in this setting should also be based on that for non–HIV-cHL, and includes the use of salvage chemotherapy followed by autologous stem cell transplant in chemosensitive disease. The role of allogeneic hematopoietic stem cell transplant is less clear but may be useful in select cases. Newer agents with activity in cHL are being tested as part of primary and salvage therapy and are also highly relevant for HIV-cHL.

show abstract

Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study

Abstract: In patients with HIV-HL, stage- and risk-adapted treatment is feasible and effective. The prognosis for patients with HIV-HL may approach that of HIV-negative patients with HL.

Cited by 112 publications

References 26 publications

HIV-Associated Malignant Lymphoma

HIV-Associated Malignant Lymphoma

HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy

How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus

Contact Info

Product

Resources

About